NewBridge Pharmaceuticals

Immunology

Rheumatology & Psoriasis

Brand Name	Description
Bimzelx® (bimekizumab)	Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy
Cimzia® (certolizumab pegol)	Cimzia, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. The treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs. Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis (AS), comprising, Adults with severe active AS who have had an inadequate response to or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). And Adults with severe active AS without radiographic evidence of AS but with objective signs of inflammation who have had an inadequate response to, or are intolerant to NSAIDs. Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Brand Name

Description

Bimzelx®
(bimekizumab)

Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Cimzia®
(certolizumab pegol)

Cimzia, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. The treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs. Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis (AS), comprising, Adults with severe active AS who have had an inadequate response to or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). And Adults with severe active AS without radiographic evidence of AS but with objective signs of inflammation who have had an inadequate response to, or are intolerant to NSAIDs. Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

For more information on any of the Newbridge Pharmaceuticals in-licensed products, please contact us on [email protected]

DISCLAIMER

Expand| Collapse

THE MEDICAL INFORMATION AVAILABLE ON THIS WEBSITE IS FOR GENERAL INFORMATION ONLY AND IS NOT A SUBSTITUTE OR REPLACEMENT FOR A MEDICAL CONSULTATION, NOR DOES IT CONSTITUTE ADVICE, RECOMMENDATION OR SUGGESTION FOR SELF-PRESCRIPTION OR SELF-MEDICATION.
USERS SHOULD NOT USE THIS INFORMATION TO ASSESS, DIAGNOSE OR TREAT ANY MEDICAL COMPLAINT AND PATIENTS MUST SEEK PROFESSIONAL ADVICE FROM A QUALIFIED PHYSICIAN BEFORE TAKING ANY ACTION IN RESPECT OF INFORMATION PROVIDED ON THIS WEBSITE.
THE AVAILABILITY OF PRODUCTS MARKETED BY NEWBRIDGE MAY VARY BY COUNTRY AND YOU MUST CHECK WITH YOUR LOCAL REGULATORY AUTHORITIES FOR RELEVANT INFORMATION OR VARIATIONS.
THIS WEBSITE CONTAINS INFORMATION ABOUT MEDICINAL PRODUCTS REGISTERED REGIONALLY NOT ALL OF THE PRODUCTS AND/OR INDICATIONS THAT ARE MENTIONED ON THE WEBSITE OF NEWBRIDGE ARE AVAILABLE IN ALL THE MARKETS, AS SOME OF THESE PRODUCTS ARE CURRENTLY UNDER REGISTRATION ACROSS THE MENA REGION AND ARE SUBJECT TO APPROVAL ACCORDING TO LOCAL LAWS AND REGULATIONS, AND/OR MAY BE MARKETED BY COMPANIES OTHER THAN NEWBRIDGE PHARMACEUTICALS
PLEASE REFER TO YOUR LOCAL NEWBRIDGE PHARMACEUTICAL SATELLITE OFFICE TO ADVISE ON THE AVAILABILITY OF THESE PRODUCTS AND REFER TO COUNTRY SPECIFIC LOCALLY APPROVED PRESCRIBING INFORMATION FOR MORE DETAILS ON THE PRODUCT AND INDICATIONS IN YOUR COUNTRY. THE INFORMATION INCLUDED IN THIS WEBSITE IS NOT INTENDED TO CONSTITUTE PROMOTION IN ANY MANNER OF ANY OF THE DRUGS REFERENCED.
THE INFORMATION POSTED ON THIS WEBSITE IS PROVIDED FOR GENERAL INFORMATION PURPOSES ONLY. WHILST NEWBRIDGE PHARMACEUTICALS WILL MAKE EVERY REASONABLE EFFORT TO INCLUDE ACCURATE AND UP-TO-DATE INFORMATION, WE SHALL NOT HOWEVER BE LIABLE IN ANY WAY FOR ERRORS OR OMISSIONS IN THE CONTENTS OF THIS WEBSITE. ALL INFORMATION IS PROVIDED "AS IS". CONSEQUENTLY, THE INFORMATION SHOULD BE CAREFULLY EVALUATED BY SITE VISITORS AND NEWBRIDGE PHARMACEUTICALS DOES NOT PROVIDE ANY WARRANTIES ABOUT COMPLETENESS OR ACCURACY OF THE INFORMATION ON THIS WEBSITE OR ITS POSSIBLE USES.
THIS WEBSITE CONTAINS LINKS TO THIRD PARTIES' PAGES OR WEBSITES AND NEWBRIDGE PHARMACEUTICALS MAKES NO REPRESENTATION, NOR DOES IT HAVE ANY RESPONSIBILITY IN RELATION TO ANY MATERIAL OR INFORMATION YOU OBTAIN FROM ANY SUCH PAGES OR WEBSITES.